Tag: form

HOUSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Fervo Energy Company (“Fervo” or the “Company”) (NASDAQ: FRVO), a leading technology-enabled independent power producer of Enhanced Geothermal Systems (EGS), today reported financial and operational results for the first quarter ended March 31, 2026.

aranello (Italy), June 22, 2026 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company”) informs that the Company has purchased, under the Euro 250 million share buyback program announced on April 10, 2026, as the second tranche of the multi-year share buyback program of approximately Euro 3.5 billion expected to be executed by 2030 in line with the disclosure made during the 2025 Capital Markets Day (the “Second Tranche”), the additional common shares - reported in aggregate form, on a daily basis on the Euronext Milan (EXM) and on the New York Stock Exchange (NYSE) as follows:

FORM 8.3

New platform will integrate real-time field data, physics-based modeling, and AI to advance critical geothermal infrastructure and maximize power generation

Sanofi appoints Paulo Fontoura as Global Head of R&D

NEW YORK, June 21, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Graphic Packaging Holding Company (NYSE: GPK) between February 4, 2025 and February 2, 2026, inclusive (the “Class Period”), of the important July 6, 2026 lead plaintiff deadline.

DUBAI, United Arab Emirates, June 21, 2026 (GLOBE NEWSWIRE) --

Pepeto just passed $10.29 million raised, the fastest fill among presales this cycle, and the reason comes down to one number every holder keeps calculating, because the wallets pouring in are large addresses that held BTC and ETH through full bear stretches and the spread between this entry and the listing price is what keeps pulling them in.

SAN CARLOS, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 18, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 140,860 shares of Iovance’s common stock to twenty-seven new, non-executive employees.